Business Context and Reporting Period
Company: TriSalus Life Sciences, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: January 31, 2025 (Event Date: February 3, 2025)
Context: The Company is an emerging growth company incorporated in Delaware. This filing reports a specific financing event rather than a standard periodic financial report.
Key Financial Metrics
This filing does not provide comprehensive financial statements, revenue, profit, cash flow, or margin data. The sole financial metric disclosed is:
- Debt Financing: The Company announced a requested drawdown under its Credit Agreement with OrbiMed, a healthcare investment firm.
Note: Specific dollar amounts for the drawdown, total debt levels, or liquidity positions are not stated in the text of this 8-K filing.
Material Changes
The material change reported is the execution of a drawdown on the Company's existing credit facility with OrbiMed. No comparative period data or year-over-year financial changes are included in this document.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) for details regarding the credit drawdown but does not include forward-looking guidance or operational outlook within the body of this report.
Risks and Contingencies: The filing explicitly states that the information in Item 2.02 and Exhibit 99.1 is "furnished" and not "filed" for purposes of Section 18 of the Exchange Act, limiting the legal liability associated with these specific disclosures.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated February 3, 2025) to determine the specific amount of the credit drawdown.
- Verify the total outstanding balance and remaining availability under the OrbiMed Credit Agreement.
- Check subsequent filings (e.g., 10-Q or 10-K) for the impact of this drawdown on the Company's liquidity and debt covenants.
- Confirm the current trading status of Common Stock (TLSI) and Warrants (TLSIW) on the Nasdaq Global Market.